The effect of monitoring of tobramycin levels in blood in patients with cystic fibrosis.

The effect of Therapeutic Drug Monitoring of tobramycin in patients with cystic fibrosis.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON20263

Enrollment

Registered

2014-05-04

Start date

2014-05-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic fibrosis

Interventions

No interventions: retrospective, observational study

Eligibility

Inclusion criteria

Inclusion criteria: - Patients with cystic fibroses. - Treatment with tobramycin - Plasma concentration of tobramycine routinely measured

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Plasma tobramycine levels within the target range	—

Secondary

Measure	Time frame
Influence of different parameter like e.g. weight, kidney function, male/female on the dosage.	—

Contacts

Public ContactE.M. Kemper

Hospital Pharmacy, AMC Meibergdreef 9

e.m.kemper@amc.nl020-5667955

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)